Navigation Links
Cerecor Announces Initiation of CLIN01-002-A
Date:5/21/2012

BALTIMORE, May 21, 2012 /PRNewswire/ -- Cerecor Inc., a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system, today announced that it has begun dosing of FP01 lozenges in CLIN01-002-A, an exploratory Phase II acute cough study in healthy subjects with upper respiratory tract infections (URTI).  "The data we plan to generate from this and subsequent studies will educate us on the safety and tolerability of FP01, in addition to quantifying the effect size of this novel product for cough," stated Dr. Blake Paterson, CEO of Cerecor. "Advancing FP01 into clinical trials represents a significant milestone both in our Company's history and in the establishment of our clinical pipeline," said Dr. Paterson. "We look forward to rapidly generating the clinical data necessary for the continued development of FP01 lozenges as a potential therapy for chronic and acute cough." 

(Logo:  http://photos.prnewswire.com/prnh/20120411/PH85852LOGO )

Cerecor Inc. ("Cerecor" or the "Company") is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system. Cerecor is focused on translational medicine -- the accelerated transfer of technology from the academic laboratory to early human trials, with the goal of rapid commercialization. Cerecor's product pipeline also includes preclinical drug development candidates in cognition and schizophreniawww.cerecor.com

For More Information, contact:
John Dierkes
'/>"/>

SOURCE Cerecor Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cerecor Announces Clearance of IND for FP01
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)...  Unilife Corporation ("Unilife" or "Company") (NASDAQ: ... of injectable drug delivery systems, today announced an ... facilities in response to increasing demand from pharmaceutical ... During the fourth quarter of fiscal year 2014, ... expenditures and R&D above normal quarterly investments. ...
(Date:7/30/2014)... N.Y. , July 30, 2014 /PRNewswire-iReach/ -- ... -based medical device company, has announced today ... the velox CD™ Vascular Closure Device. Velox CD™ ... immediate hemostasis following percutaneous femoral procedures. The single ... broadly ranging in size from 5F to 8F.  ...
(Date:7/30/2014)... -- InnoPharma, Inc. today announced the first generic launch of ... injection), in Canada.  Olanzapine is indicated for the rapid ... schizophrenia or bipolar I mania. As the ... into an agreement with Sandoz Canada Inc., pursuant to ... market and distribute Olanzapine Injection in Canada ...
Breaking Medicine Technology:Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 2Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 3Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 4Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 5Transluminal Technologies receives CE Mark approval for velox CD(TM) vascular closure device 2InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2
... Ill., Dec. 21, 2010 The American Veterinary Medical Association ... new federal guidelines on a useful and effective induction agent, ... making propofol a Schedule IV drug.  In a letter to ... the DEA keep this effective drug, which typically causes few ...
... Dec. 21, 2010 Based on its recent ... & Sullivan recognizes Cambridge, Mass.-based Semprus BioSciences with ... Award for Surface Functionalization Technologies . The company,s ... designed to reduce the complications associated with implanted ...
Cached Medicine Technology:AVMA Offers Important Guidance to DEA on New Controls for Induction Agent—Propofol 2Frost & Sullivan Presents the 2010 North American Enabling Technology of the Year Award for Surface Functionalization Technologies to Semprus BioSciences 2Frost & Sullivan Presents the 2010 North American Enabling Technology of the Year Award for Surface Functionalization Technologies to Semprus BioSciences 3
(Date:7/30/2014)... (PRWEB) July 30, 2014 Volunteers from ... to counter drug abuse this summer with massive distribution ... , You can find these volunteers on Strøget, the ... residents alike for its shopping and its ambiance, some ... on a typical summer day. , These activities ...
(Date:7/30/2014)... mutationslong known to fuel cancer as well as evolutionary ... rare events that occur randomly throughout the genome. , ... involves the formation of multiple mutations that arise simultaneously ... of clustered mutations are frequently found in regions where ... the journal Cell Reports , may one day ...
(Date:7/30/2014)... MA (PRWEB) July 30, 2014 ... of authentication, access management and secure communications solutions ... Imprivata OneSign ® is the most widely selected ... McKesson Paragon or Horizon electronic medical records (EMR) ... increase of about 11 percent in the last ...
(Date:7/30/2014)... IN (PRWEB) July 30, 2014 ... the opening of its new Carmel office on July ... staff will finally be moving to the state-of-the-art suite, ... cozy and innovative space will allow for one-on-one patient ... cosmetic surgery experience. , Dr. Hamilton’s new office-suite ...
(Date:7/30/2014)... caught it early" is possibly the best news a ... diagnosis. Combating cancer in its earliest stages, when the ... body, gives patients the best chances of survival. ... forms of cancer are touted for saving lives through ... as a precautionary measure, especially for high-risk patients. But ...
Breaking Medicine News(10 mins):Health News:Biologists describe mechanism promoting multiple DNA mutations 2Health News:Imprivata Achieves 51 Percent Single Sign-on Market Share Amongst U.S. Hospitals Using McKesson Paragon or Horizon EMR Systems, According to HIMSS Analytics 2Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 3
... common among prisoners than among the general population of Thailandone ... found that 25% of prisoners who agreed to be tested ... in the national population. ,But Thailands prisons, say ... and severe budgetary constraints that impede the effective delivery of ...
... have been deployed worldwide to provide early detection of ... ,New methods that improve the overall detection capabilities of ... most surveillance systems do not hold up when there ... by public-health crises and major public events, such as ...
... the Archives of Internal Medicine journal, Obese or overweight ... risk of developing tuberculosis than those at a normal ... poverty and undernutrition in both developed and developing countries. ... associated with a wide range of chronic degenerative conditions, ...
... of antidepressant medications known as selective serotonin reuptake inhibitors ... loss in older men and women. Selective serotonin ... that transports serotonin, a neurotransmitter involved in sleep and ... in bone as well, raising the possibility that SSRIs ...
... of Washington shows that the work intended for global ... . ,The research was conducted by a UW ... professor in the School of Public Health and Community ... and Sally Weatherford, finance and administration director of the ...
... section does not affect infants health. The babies delivered ... early in life according to a new study. ... Hong Kong researchers found that babies delivered by C-section ... visits during their first 18 months of life. ...
Cached Medicine News:Health News:Obesity is Related to Lower Tuberculosis Risk 2Health News:Antidepressents may Lower Bone Density in Older People 2Health News:Antidepressents may Lower Bone Density in Older People 3Health News:Global Health Enriching the States Economy 2Health News:C- Section Does Not Affect an Infants Health 2
This ENDOLOOP suture has a suture type - 0 PDSII and a 1.5 inch diameter....
... long ligature inserted into a plastic tube. The plastic ... the other. The suture protrudes from the narrow end ... knot which becomes secure after the device is activated. ... the scored end of the plastic tube. The scored ...
... Panel is an enzyme immunoassay used for ... (glutamate dehydrogenase) and toxin A in human ... an aid in the diagnosis of C. ... the Triage Microbiology product line, designed to ...
ELISA for the detection of C. difficile toxin A in stool specimens...
Medicine Products: